Refine
Document Type
- Article (13)
Language
- English (13) (remove)
Has Fulltext
- yes (13)
Is part of the Bibliography
- no (13)
Keywords
- lipocalin-2 (4)
- macrophage polarization (4)
- iron (3)
- iron metabolism (3)
- standardization (2)
- tumor progression (2)
- Breast cancer (1)
- Breast tumors (1)
- CLP (1)
- FX06 (1)
- Gene expression (1)
- Immune cells (1)
- Macrophages (1)
- Messenger RNA (1)
- RNA extraction (1)
- RNA isolation (1)
- T cells (1)
- angiogenesis (1)
- apoptosis (1)
- cancer cell metabolism (1)
- chelation therapy (1)
- clinical pathways (1)
- cross-linking (1)
- disordered iron metabolism (1)
- ectosomes (1)
- endothelial activation (1)
- exosomes (1)
- extracellular vesicles (1)
- ferroportin (1)
- gastric surgery (1)
- guidelines (1)
- hypoxia (1)
- iron chelator (1)
- iron chelators (1)
- iron homeostasis (1)
- iron-trafficking (1)
- macrophage (1)
- macrophages (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- oncological gastrectomy (1)
- outcomes (1)
- phagocytosis (1)
- polymeric micelle (1)
- polypept(o)ide (1)
- primary mouse proximal tubular cells (1)
- quality of care (1)
- renal cell carcinoma (1)
- renal ischemia reperfusion injury (1)
- renal tubular epithelial cells (1)
- reproducibility (1)
- rigor (1)
- sphingosine-1-phosphate (1)
- superparamagnetic iron oxide nanoparticles (1)
- tubular regeneration (1)
- tumor microenvironment (1)
- tumor stroma (1)
- tumor-associated macrophages (1)
- tumor-associated macrophages (TAM) (1)
Institute
While aberrant cells are routinely recognized and removed by immune cells, tumors eventually escape innate immune responses. Infiltrating immune cells are even corrupted by the tumor to acquire a tumor-supporting phenotype. In line, tumor-associated macrophages are well-characterized to promote tumor progression and high levels of tumor-infiltrating macrophages are a poor prognostic marker in breast cancer. Here, we aimed to further decipher the influence of macrophages on breast tumor cells and determined global gene expression changes in three-dimensional tumor spheroids upon infiltration of macrophages. While various tumor-associated mRNAs were upregulated, expression of the cytochrome P450 family member CYP1A1 was markedly attenuated. Repression of CYP1A1 in tumor cells was elicited by a macrophage-shaped tumor microenvironment rather than by direct tumor cell-macrophage contacts. In line with changes in RNA expression profiles, macrophages enhanced proliferation of the tumor cells. Enhanced proliferation and macrophage presence further correlated with reduced CYP1A1 expression in patient tumors when compared with normal tissue. These findings are of interest in the context of combinatory therapeutic approaches involving cytotoxic and immune-modulatory compounds.
Iron is an essential co-factor for cellular processes. In the immune system, it can activate macrophages and represents a potential therapeutic for various diseases. To specifically deliver iron to macrophages, iron oxide nanoparticles are embedded in polymeric micelles of reactive polysarcosine-block-poly(S-ethylsulfonyl-l-cysteine). Upon surface functionalization via dihydrolipoic acid, iron oxide cores act as crosslinker themselves and undergo chemoselective disulfide bond formation with the surrounding poly(S-ethylsulfonyl-l-cysteine) block, yielding glutathione-responsive core cross-linked polymeric micelles (CCPMs). When applied to primary murine and human macrophages, these nanoparticles display preferential uptake, sustained intracellular iron release, and induce a strong inflammatory response. This response is also demonstrated in vivo when nanoparticles are intratracheally administered to wild-type C57Bl/6N mice. Most importantly, the controlled release concept to deliver iron oxide in redox-responsive CCPMs induces significantly stronger macrophage activation than any other iron source at identical iron levels (e.g., Feraheme), directing to a new class of immune therapeutics.
Early and adequate restoration of endothelial and tubular renal function is a substantial step during regeneration after ischemia reperfusion (IR) injury, occurring, e.g., in kidney transplantation, renal surgery, and sepsis. While tubular epithelial cell injury has long been of central importance, recent perception includes the renal vascular endothelium. In this regard, the fibrin cleavage product fibrinopeptide Bβ15-42 mitigate IR injury by stabilizing interendothelial junctions through its affinity to VE-cadherin. Therefore, this study focused on the effect of Bβ15-42 on post-acute physiological renal regeneration. For this, adult male C57BL/6 mice were exposed to a 30 min bilateral renal ischemia and reperfusion for 24 h or 48 h. Animals were randomized in a non-operative control group, two operative groups each treated with i.v. administration of either saline or Bβ15-42 (2.4 mg/kg) immediately prior to reperfusion. Endothelial activation and inflammatory response was attenuated in renal tissue homogenates by single application of Bβ15-42. Meanwhile, Bβ15-42 did not affect acute kidney injury markers. Regarding the angiogenetic players VEGF-A, Angiopoietin-1, Angiopoietin-2, however, we observed significant higher expressions at mRNA and trend to higher protein level in Bβ15-42 treated mice, compared to saline treated mice after 48 h of IR, thus pointing toward an increased angiogenetic activity. Similar dynamics were observed for the intermediate filament vimentin, the cytoprotective protein klotho, stathmin and the proliferation cellular nuclear antigen, which were significantly up-regulated at the same points in time. These results suggest a beneficial effect of anatomical contiguously located endothelial cells on tubular regeneration through stabilization of endothelial integrity. Therefore, it seems that Bβ15-42 represents a novel pharmacological approach in the targeted therapy of acute renal failure in everyday clinical practice.